



## Supplemental Figure S1



### Figure S1. MHCII expressions didn't reduce in TSC1 KO BMM $\phi$ and B cells.

(A) Both TSC1 KO and WT BMM $\phi$  were treated with LPS at 10ng/ml for indicated times. The total RNA was extracted from these cells and subjected to real-time qPCR analyses for mRNA levels of MHCII $\alpha$ , MHCII $\beta$ , CIITA, and IRF4. (B) Both TSC1 KO and WT splenic B cells were purified and treated with LPS at 100ng/mL overnight. The cells were harvested and washed and then stained with MHCI, MHCII, CD80 and Cd86 antibodies and analyzed by flow cytometry. (C) CIITA and IRF4 mRNA levels in WT and TSC1 KO B cells measured by real-time qPCR.

## Supplemental Figure S2



### Figure S2. Assessment of BMDCs without tamoxifen-induced deletion.

BMDCs were generated from *TSC1f/f* and *TSC1f/f-ERCre* mice without tamoxifen treatment. (A) MHCII and CD86 expression in DCs unstimulated or treated with LPS at 10ng/ml overnight. Overlaid histograms show CD86 and MHCII expression on gated CD11C<sup>+</sup> DCs. (B) CD25 expression on OTII T cells cultured overnight with LPS primed DCs pulsed with or without OVA<sub>323-339</sub>. (C) CFSE dilution of OTII T cells. CFSE-labeled OTII T cells were stimulated with DCs similarly pretreated as in (B). CFSE dilution was measured after 72 hour stimulation. Data show represent two experiments.